Free Trial
Your $100 Credit Expires Tomorrow! Get MarketBeat All Access
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Don't Miss Out
Claim MarketBeat All Access Sale Promotion

Cassava Sciences (FLNA) Competitors

Cassava Sciences logo
$1.31 +0.02 (+1.55%)
As of 05/22/2026 04:00 PM Eastern

FLNA vs. HELP, ALEC, NERV, CHRS, and CNTN

Should you buy Cassava Sciences stock or one of its competitors? MarketBeat compares Cassava Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cassava Sciences include Cybin (HELP), Alector (ALEC), Minerva Neurosciences (NERV), Coherus Oncology (CHRS), and Hillstream Biopharma (CNTN). These companies are all part of the "pharmaceutical products" industry.

How does Cassava Sciences compare to Cybin?

Cassava Sciences (NASDAQ:FLNA) and Cybin (NASDAQ:HELP) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.

In the previous week, Cassava Sciences' average media sentiment score of 0.00 equaled Cybin'saverage media sentiment score.

Company Overall Sentiment
Cassava Sciences Neutral
Cybin Neutral

Cassava Sciences' return on equity of -53.90% beat Cybin's return on equity.

Company Net Margins Return on Equity Return on Assets
Cassava SciencesN/A -53.90% -34.20%
Cybin N/A -59.98%-50.80%

Cassava Sciences has a beta of -0.75, indicating that its share price is 175% less volatile than the broader market. Comparatively, Cybin has a beta of 0.8, indicating that its share price is 20% less volatile than the broader market.

Cybin has a consensus target price of $58.75, indicating a potential upside of 1,155.34%. Given Cybin's stronger consensus rating and higher probable upside, analysts plainly believe Cybin is more favorable than Cassava Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cassava Sciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Cybin
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00

38.1% of Cassava Sciences shares are held by institutional investors. Comparatively, 17.9% of Cybin shares are held by institutional investors. 4.6% of Cassava Sciences shares are held by company insiders. Comparatively, 15.0% of Cybin shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Cybin is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cassava SciencesN/AN/A-$90.97M-$1.61N/A
CybinN/AN/A-$81.31M-$4.23N/A

Summary

Cybin beats Cassava Sciences on 6 of the 11 factors compared between the two stocks.

How does Cassava Sciences compare to Alector?

Cassava Sciences (NASDAQ:FLNA) and Alector (NASDAQ:ALEC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership.

In the previous week, Cassava Sciences' average media sentiment score of 0.00 equaled Alector'saverage media sentiment score.

Company Overall Sentiment
Cassava Sciences Neutral
Alector Neutral

Cassava Sciences has higher earnings, but lower revenue than Alector. Alector is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cassava SciencesN/AN/A-$90.97M-$1.61N/A
Alector$21.05M11.66-$142.93M-$1.19N/A

Cassava Sciences has a beta of -0.75, meaning that its share price is 175% less volatile than the broader market. Comparatively, Alector has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market.

Cassava Sciences has a net margin of 0.00% compared to Alector's net margin of -680.83%. Cassava Sciences' return on equity of -53.90% beat Alector's return on equity.

Company Net Margins Return on Equity Return on Assets
Cassava SciencesN/A -53.90% -34.20%
Alector -680.83%-295.17%-40.95%

Alector has a consensus target price of $3.63, suggesting a potential upside of 64.03%. Given Alector's stronger consensus rating and higher probable upside, analysts clearly believe Alector is more favorable than Cassava Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cassava Sciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Alector
2 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.13

38.1% of Cassava Sciences shares are held by institutional investors. Comparatively, 85.8% of Alector shares are held by institutional investors. 4.6% of Cassava Sciences shares are held by insiders. Comparatively, 8.3% of Alector shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Alector beats Cassava Sciences on 8 of the 13 factors compared between the two stocks.

How does Cassava Sciences compare to Minerva Neurosciences?

Minerva Neurosciences (NASDAQ:NERV) and Cassava Sciences (NASDAQ:FLNA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Minerva Neurosciences currently has a consensus target price of $10.50, suggesting a potential upside of 99.62%. Given Minerva Neurosciences' stronger consensus rating and higher probable upside, research analysts clearly believe Minerva Neurosciences is more favorable than Cassava Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Minerva Neurosciences
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Cassava Sciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Cassava Sciences is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Minerva NeurosciencesN/AN/A-$293.42M-$29.16N/A
Cassava SciencesN/AN/A-$90.97M-$1.61N/A

In the previous week, Minerva Neurosciences had 11 more articles in the media than Cassava Sciences. MarketBeat recorded 11 mentions for Minerva Neurosciences and 0 mentions for Cassava Sciences. Minerva Neurosciences' average media sentiment score of 0.74 beat Cassava Sciences' score of 0.00 indicating that Minerva Neurosciences is being referred to more favorably in the media.

Company Overall Sentiment
Minerva Neurosciences Positive
Cassava Sciences Neutral

34.6% of Minerva Neurosciences shares are owned by institutional investors. Comparatively, 38.1% of Cassava Sciences shares are owned by institutional investors. 10.4% of Minerva Neurosciences shares are owned by insiders. Comparatively, 4.6% of Cassava Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Minerva Neurosciences has a beta of -0.08, meaning that its stock price is 108% less volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.75, meaning that its stock price is 175% less volatile than the broader market.

Minerva Neurosciences' return on equity of 0.00% beat Cassava Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Minerva NeurosciencesN/A N/A -32.63%
Cassava Sciences N/A -53.90%-34.20%

Summary

Minerva Neurosciences beats Cassava Sciences on 10 of the 13 factors compared between the two stocks.

How does Cassava Sciences compare to Coherus Oncology?

Cassava Sciences (NASDAQ:FLNA) and Coherus Oncology (NASDAQ:CHRS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

In the previous week, Cassava Sciences' average media sentiment score of 0.00 equaled Coherus Oncology'saverage media sentiment score.

Company Overall Sentiment
Cassava Sciences Neutral
Coherus Oncology Neutral

Cassava Sciences has a beta of -0.75, suggesting that its share price is 175% less volatile than the broader market. Comparatively, Coherus Oncology has a beta of 1.01, suggesting that its share price is 1% more volatile than the broader market.

Coherus Oncology has a consensus price target of $8.67, suggesting a potential upside of 438.30%. Given Coherus Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Coherus Oncology is more favorable than Cassava Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cassava Sciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Coherus Oncology
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75

Coherus Oncology has a net margin of 397.30% compared to Cassava Sciences' net margin of 0.00%. Cassava Sciences' return on equity of -53.90% beat Coherus Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Cassava SciencesN/A -53.90% -34.20%
Coherus Oncology 397.30%-198.90%-46.65%

Coherus Oncology has higher revenue and earnings than Cassava Sciences. Cassava Sciences is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cassava SciencesN/AN/A-$90.97M-$1.61N/A
Coherus Oncology$42.17M5.89$168.02M$1.670.96

38.1% of Cassava Sciences shares are owned by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are owned by institutional investors. 4.6% of Cassava Sciences shares are owned by insiders. Comparatively, 8.1% of Coherus Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Coherus Oncology beats Cassava Sciences on 11 of the 13 factors compared between the two stocks.

How does Cassava Sciences compare to Hillstream Biopharma?

Cassava Sciences (NASDAQ:FLNA) and Hillstream Biopharma (NASDAQ:CNTN) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

In the previous week, Hillstream Biopharma had 2 more articles in the media than Cassava Sciences. MarketBeat recorded 2 mentions for Hillstream Biopharma and 0 mentions for Cassava Sciences. Cassava Sciences' average media sentiment score of 0.00 beat Hillstream Biopharma's score of -0.18 indicating that Cassava Sciences is being referred to more favorably in the media.

Company Overall Sentiment
Cassava Sciences Neutral
Hillstream Biopharma Neutral

Cassava Sciences has a beta of -0.75, suggesting that its share price is 175% less volatile than the broader market. Comparatively, Hillstream Biopharma has a beta of 1.44, suggesting that its share price is 44% more volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cassava Sciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Hillstream Biopharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Hillstream Biopharma's return on equity of -31.50% beat Cassava Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Cassava SciencesN/A -53.90% -34.20%
Hillstream Biopharma N/A -31.50%-24.72%

Hillstream Biopharma is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cassava SciencesN/AN/A-$90.97M-$1.61N/A
Hillstream BiopharmaN/AN/A-$35.92M-$1.15N/A

38.1% of Cassava Sciences shares are owned by institutional investors. Comparatively, 1.2% of Hillstream Biopharma shares are owned by institutional investors. 4.6% of Cassava Sciences shares are owned by insiders. Comparatively, 6.7% of Hillstream Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Hillstream Biopharma beats Cassava Sciences on 7 of the 10 factors compared between the two stocks.

Get Cassava Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for FLNA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FLNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FLNA vs. The Competition

MetricCassava SciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$63.28M$3.04B$6.44B$12.34B
Dividend YieldN/A1.97%2.76%5.28%
P/E Ratio-0.8118.0421.2625.66
Price / SalesN/A336.21552.9986.26
Price / CashN/A57.7443.6856.73
Price / Book0.935.8610.367.14
Net Income-$90.97M$74.99M$3.56B$335.80M
7 Day Performance11.02%0.37%5.12%3.02%
1 Month Performance-18.63%-2.99%3.54%2.48%
1 Year Performance-37.91%34.38%34.14%35.08%

Cassava Sciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FLNA
Cassava Sciences
0.1339 of 5 stars
$1.31
+1.6%
N/A-37.9%$63.28MN/AN/A20
HELP
Cybin
3.1209 of 5 stars
$4.54
-2.8%
$58.75
+1,194.1%
N/A$234.40MN/AN/A50
ALEC
Alector
3.0948 of 5 stars
$2.11
-2.5%
$3.63
+72.2%
+78.2%$233.72M$21.05MN/A270
NERV
Minerva Neurosciences
2.5693 of 5 stars
$4.99
-4.3%
$10.50
+110.5%
+260.3%$232.34MN/AN/A9
CHRS
Coherus Oncology
2.5423 of 5 stars
$1.51
-4.1%
$8.67
+475.9%
+112.9%$232.15M$42.17M0.90330

Related Companies and Tools


This page (NASDAQ:FLNA) was last updated on 5/24/2026 by MarketBeat.com Staff.
From Our Partners